Last reviewed · How we verify

C. R. Bard — Portfolio Competitive Intelligence Brief

C. R. Bard pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ChloraPrep One-Step ChloraPrep One-Step marketed Topical antiseptic Infection Prevention / Surgical Prophylaxis

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Central DuPage Hospital · 1 shared drug class
  2. Instituto de Investigacion Sanitaria La Fe · 1 shared drug class
  3. Johnson & Johnson Consumer Inc. (J&JCI) · 1 shared drug class
  4. Poitiers University Hospital · 1 shared drug class
  5. Professional Disposables International, Inc. · 1 shared drug class
  6. Solventum US LLC · 1 shared drug class
  7. University of British Columbia · 1 shared drug class
  8. University of Iowa · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for C. R. Bard:

Cite this brief

Drug Landscape (2026). C. R. Bard — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/c-r-bard. Accessed 2026-05-15.

Related